Therapeutic Areas
hVIVO delivers specialist clinical expertise across four major therapeutic areas: infectious diseases, respiratory medicine, cardiometabolic disorders, and renal/hepatic impairment. Each area is underpinned by deep scientific leadership, dedicated clinical infrastructure, and extensive access to well‑characterised patient populations. Our integrated model—combining clinical sites, specialised assessments, laboratory capabilities, PK/PD consultancy, and end‑to‑end operational delivery—enables accelerated recruitment, high‑resolution data generation, and efficient execution of early‑phase to mechanistic studies. With decades of experience across these therapeutic areas, hVIVO provides clients with the precision, speed, and scientific depth required to advance novel vaccines, therapeutics, and metabolic or organ‑function interventions.
- Global leader in infectious disease and human challenge models
- 400,000+ active respiratory volunteers with advanced airway assessment capabilities
- Centre of Excellence for renal & hepatic impairment with patients
- Specialist cardiometabolic research supported by 30+ years of scientific leadership
Contact our Therapeutic Area Specialists
Have a question?
Therapeutic Areas
Infectious Disease
hVIVO leads infectious disease research with industry‑leading human challenge models, BSL -2 & 3 facilities, and end‑to‑end vaccine and therapeutic development expertise.
Cardio-Metabolic
hVIVO is a specialist in cardiometabolic clinical studies, offering a broad spectrum of pharmacodynamic assessments in the indication of obesity, insulin resistance, endothelial dysfunction, diabetes, lipid disorders, hypertension, or Metabolic Dysfunction associated steatotic liver disease (MASLD).
Respiratory
We deliver high-quality respiratory clinical trials supported by expert investigators, specialised lung‑function assessments, and one of the UK’s largest active databases of patients with asthma, COPD, and atopic respiratory conditions.
Renal & Hepatic
hVIVO Kiel is a dedicated Centre of Excellence for renal and hepatic impairment clinical pharmacology.
Yes — our teams manage both HV and special populations including renal/hepatic impairment, elderly cohorts, and women specific studies.
Contact Our Team
Submit your RFI/RFP Request